Nexalin Technology, Inc. NXL
NASDAQ · United States · Health Technology
$5.73-1.82 (-24.11%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Nexalin Technology (NXL) signed an agreement to appoint Inovanexa Medical Technologies as its exclus
The 10-year exclusive agreement covers seven countries and includes an initial binding device order, a Brazilian clinical pilot and a framework for locally manufactured devices and recurring electrode royalties. Key Investor TakeawaysNexalin Technology (NASDAQ:NXL) signed a definitive exclusive South America distribution agreement with Inovanexa Medical Technologies covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum re
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.